Researchers conducted this study to assess its safety and effectiveness.

A prospective clinical trial was conducted in a single medical center in 2016–2018. The study included 30 patients with a mean age of 41.9 years, who were scheduled for bilateral ESS, were randomized to undergo composite sinus stent implantation for 14 to 28 days or middle meatus placement of a Telfa tampon. Telfa is a non-adherent absorbent dressing that has been compared favorably with other packs for use following ESS. Both groups received the same postoperative treatment. 

The stent was successfully implanted and removed in all twenty-nine treated sinuses, without complications. None of the stents showed granulation tissue or crusting. Compared to the tampon group, the stent group had significantly less inflammation. The probability of having adhesion was 9.3 times greater in the control group than the study group. Patients who underwent stent implantation experienced higher symptomatic improvement. During stent implantation, patients did not suffer from any discomfort.

The composite sinus stent is safer and more effective than the Telfa tampon in maintaining sinus cavity patency and promoting healing following ESS.